Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
By P. Tomasini, L. Greillier, Arnaud Boyer, Arnaud Jeanson, F. Barlesi. Journal of Thoracic Disease, 2018
1,670 citations recorded by the source corpus.
Immune Check Point inhibitors (ICIs) have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors being the most studied drugs.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/fe5bb569cb4d93de8c4ebb114c22b48eca6f56b3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- The emerging treatment landscape of targeted therapy in non-small-cell lung cancer (2019, positive): “Another phase III study (PACIFIC) will compare the PD-L1 inhibitor durvalumab versus placebo in unresectable stage III NSCLC patients following chemoradiation adjuvant therapy.(161) The interim analysis of the PACIFIC trial has reported a median PFS of 16.”
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “advanced melanoma, non-small cell lung cancer (NSCLC), urothelial cancer (UC), renal cell carcinoma (RCC), and other cancer types [1-8].”
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, background): “Although not FDA approved, it is worthwhile to mention that the PD-L1 inhibitor durvalumab was recently granted FDA breakthrough designation in the adjuvant treatment of locally advanced, unresectable NSCLC based on the phase III PACIFIC trial [31].”